Faron Pharmaceuticals Ltd: Half-Year Financial Results 1 January - 30 June 2025

▤ Summary

Faron Pharmaceuticals reported its half-year 2025 results and highlighted major progress for its lead immunotherapy bexmarilimab. The company completed enrollment in key BEXMAB studies, secured orphan drug designations from the EMA and FDA, and received positive phase II data that supports a registrational phase II/III path in high-risk MDS. Faron also strengthened its balance sheet through a EUR 12 million placement and a convertible bond arrangement, extending cash runway into 2026. The company expanded its leadership team, advanced solid tumor programs, and continued partnering discussions as it prepares for the next development phase.

▦ Linked Companies